This is a preview of subscription content, log in via an institution to check access.
References
Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: non-compliance, non-absorption, nonresponse. Br J Clin Pharmacol 2002; 54: 212–220
Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601–615
Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005 Oct 19; (4): CD0000ll
Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508–515
Claxton AJ, Cramer JA, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310
Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453–1460
Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307–2335
Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315–1322
Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. 18th ed. New York: Ardent Media, 2004
National Collaborating Centre for Women’s and Children’s Health. Long-acting reversible contraception: the effective and appropriate use of long-term reversible contraception. London: RCOG Press, 2005
Ome P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111–117
Joint Formulary Committee. British national formulary. 50th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005 [online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2006 Jan 23]
Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3–16
Wetzels GE, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–1855
Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366: 2005–2011
Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998; 33: 207–219
Summary of product characteristics: Bonviva 150mg film-coated tablets. Welwyn Garden City: Roche Products Limited, 2005 [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2006 Jan 23]
Acknowledgements
The author has received research funding from Janssen Pharmaceutica, manufacturers of risperidone. No sources of funding were used to assist in the preparation of this editorial. The author has no conflicts of interest relevant to this editorial.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hughes, D. Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?. Pharmacoeconomics 24, 211–213 (2006). https://doi.org/10.2165/00019053-200624030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200624030-00001